Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2017

28.11.2016 | Head and Neck Oncology

Clinical Outcomes of Taiwanese Patients with cT4 Oral Cavity Squamous Cell Carcinoma: Toward the Identification of the Optimal Initial Treatment Approach for cT4b Patients

verfasst von: Chun-Ta Liao, MD, Yu-Wen Wen, PhD, Shu Ru Lee, PhD, Tsang-Wu Liu, MD, Sen-Tien Tsai, MD, Ming-Hsui Tsai, MD, Jin-Ching Lin, MD, Pei-Jen Lou, MD, PhD, Pen-Yuan Chu, MD, Yi-Shing Leu, MD, Kuo-Yang Tsai, MD, Shyuang-Der Terng, MD, Tsung-Ming Chen, MD, Cheng-Hsu Wang, MD, Chih-Yen Chien, MD, Wen-Cheng Chen, MD, Li-Yu Lee, MD, Chien-Yu Lin, MD, PhD, Hung-Ming Wang, MD, Shu-Hang Ng, MD, Chih-Hung Lin, MD, Tuan-Jen Fang, MD, Shiang-Fu Huang, MD, PhD, Chung-Jan Kang, MD, Kai-Ping Chang, MD, PhD, Lan Yan Yang, PhD, Tzu-Chen Yen, MD, PhD, for the Taiwan Oral Cancer Advisory Group

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The National Comprehensive Cancer Network guidelines recommend that patients with oral cavity squamous cell carcinoma (OSCC) and cT4b disease should be either included in clinical trials or treated with a nonsurgical approach. However, surgery may be feasible in selected patients with adequate safety margins. Using the nationwide Taiwanese Cancer Registry Database, we examined the prognosis of cT4b OSCC patients in relation to their treatment approach.

Methods

Of the 18,910 patients with previously untreated first primary OSCC identified between 2004 and 2010, 492 (2.6 %) had cT4b tumors. Of them, 327 (66 %) received initial treatment with surgery, whereas 165 (34 %) were initially treated with a nonsurgical approach. Of the latter group, 78 patients subsequently underwent surgery. A 5-year disease-specific survival (DSS) ≥45 % was considered as a favorable outcome.

Results

Better 5-year DSS and overall survival (OS) rates were observed in cT4b patients initially treated with surgery (vs. nonsurgery; DSS, 51 vs. 38 %; OS, 43 vs. 27 %, respectively, p < 0.001). Of the participants initially treated with surgery, patients with cN0–2 disease had better 5-year survival rates (DSS: cN0, 59 %; cN1, 53 %; cN2, 46 %; OS: cN0, 49 %; cN1, 50 %; cN2, 37 %) than those with cN3 disease (DSS: 0 %; OS: 0 %). Among cT4b patients who initially received a nonsurgical treatment, subjects who subsequently underwent surgery showed better outcomes.

Conclusions

Primary surgery is performed in approximately two-thirds of cT4b OSCC patients, with cN0–2 cases showing a good prognosis. Patients who initially received a nonsurgical approach can subsequently be treated with surgery and achieve favorable outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Liao CT, Wang HM, Ng SH, et al. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. Oral Oncol. 2006;42:800–9.CrossRefPubMed Liao CT, Wang HM, Ng SH, et al. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. Oral Oncol. 2006;42:800–9.CrossRefPubMed
2.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
3.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010.
5.
Zurück zum Zitat Kreppel M, Amir Manawi NN, Scheer M, et al. Prognostic quality of the Union Internationale Contre le Cancer/American Joint Committee on Cancer TNM classification, 7th edition, for cancer of the maxillary sinus. Head Neck. 2015;37:400–6. Kreppel M, Amir Manawi NN, Scheer M, et al. Prognostic quality of the Union Internationale Contre le Cancer/American Joint Committee on Cancer TNM classification, 7th edition, for cancer of the maxillary sinus. Head Neck. 2015;37:400–6.
6.
Zurück zum Zitat Patil VM, Prabhash K, Noronha V, et al. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol. 2014;50:1000–4.CrossRefPubMed Patil VM, Prabhash K, Noronha V, et al. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol. 2014;50:1000–4.CrossRefPubMed
7.
Zurück zum Zitat Joshi A, Patil VM, Noronha V, et al. Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers? Indian J Cancer. 2013;50:349–55.CrossRefPubMed Joshi A, Patil VM, Noronha V, et al. Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers? Indian J Cancer. 2013;50:349–55.CrossRefPubMed
8.
Zurück zum Zitat Trivedi NP, Kekatpure V, Kuriakose MA. Radical (compartment) resection for advanced buccal cancer involving masticator space (T4b): our experience in thirty patients. Clin Otolaryngol. 2012;37:477–83.CrossRefPubMed Trivedi NP, Kekatpure V, Kuriakose MA. Radical (compartment) resection for advanced buccal cancer involving masticator space (T4b): our experience in thirty patients. Clin Otolaryngol. 2012;37:477–83.CrossRefPubMed
9.
Zurück zum Zitat Liao CT, Lee LY, Hsueh C, et al. Comparative outcomes in oral cavity cancer with resected pT4a and pT4b. Oral Oncol. 2013;49:230–6.CrossRefPubMed Liao CT, Lee LY, Hsueh C, et al. Comparative outcomes in oral cavity cancer with resected pT4a and pT4b. Oral Oncol. 2013;49:230–6.CrossRefPubMed
10.
Zurück zum Zitat Liao CT, Ng SH, Chang JT, et al. T4b oral cavity cancer below the mandibular notch is resectable with a favorable outcome. Oral Oncol. 2007;43:570–9.CrossRefPubMed Liao CT, Ng SH, Chang JT, et al. T4b oral cavity cancer below the mandibular notch is resectable with a favorable outcome. Oral Oncol. 2007;43:570–9.CrossRefPubMed
11.
Zurück zum Zitat Liao CT, Chang JT, Wang HM, et al. Surgical outcome of T4a and resected T4b oral cavity cancer. Cancer. 2006;107:337–44.CrossRefPubMed Liao CT, Chang JT, Wang HM, et al. Surgical outcome of T4a and resected T4b oral cavity cancer. Cancer. 2006;107:337–44.CrossRefPubMed
13.
Zurück zum Zitat Liao CT, Lin CY, Fan KH, Wang HM. The optimal treatment modality for Taiwan oral cavity cancer patients—experience of a medical center. J Cancer Res Pract. 2015;2:103–16. Liao CT, Lin CY, Fan KH, Wang HM. The optimal treatment modality for Taiwan oral cavity cancer patients—experience of a medical center. J Cancer Res Pract. 2015;2:103–16.
14.
Zurück zum Zitat Hanasono MM, Friel MT, Klem C, et al. Impact of reconstructive microsurgery in patients with advanced oral cavity cancers. Head Neck. 2009;31:1289–96.CrossRefPubMed Hanasono MM, Friel MT, Klem C, et al. Impact of reconstructive microsurgery in patients with advanced oral cavity cancers. Head Neck. 2009;31:1289–96.CrossRefPubMed
15.
Zurück zum Zitat Mücke T, Wolff KD, Wagenpfeil S, Mitchell DA, Hölzle F. Immediate microsurgical reconstruction after tumor ablation predicts survival among patients with head and neck carcinoma. Ann Surg Oncol. 2010;17:287–95.CrossRefPubMed Mücke T, Wolff KD, Wagenpfeil S, Mitchell DA, Hölzle F. Immediate microsurgical reconstruction after tumor ablation predicts survival among patients with head and neck carcinoma. Ann Surg Oncol. 2010;17:287–95.CrossRefPubMed
16.
Zurück zum Zitat Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med. 2015;372:2229–34.CrossRefPubMed Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med. 2015;372:2229–34.CrossRefPubMed
17.
Zurück zum Zitat Tan DS, Mok TS, Rebbeck TR. Cancer genomics: diversity and disparity across ethnicity and geography. J Clin Oncol. 2016;34:91–101.CrossRefPubMed Tan DS, Mok TS, Rebbeck TR. Cancer genomics: diversity and disparity across ethnicity and geography. J Clin Oncol. 2016;34:91–101.CrossRefPubMed
18.
Zurück zum Zitat Chen SJ, Liu H, Liao CT, et al. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature. Oncotarget. 2015;20 6:18066–80.CrossRef Chen SJ, Liu H, Liao CT, et al. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature. Oncotarget. 2015;20 6:18066–80.CrossRef
19.
Zurück zum Zitat Peng CH, Liao CT, Ng KP, et al. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma. Oncotarget. 2015;14 6:19891–906.CrossRef Peng CH, Liao CT, Ng KP, et al. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma. Oncotarget. 2015;14 6:19891–906.CrossRef
20.
Zurück zum Zitat Liao CT, Chen SJ, Lee LY, et al. An ultra-deep targeted sequencing gene panel improves the prognostic stratification of patients with advanced oral cavity squamous cell carcinoma. Medicine. 2016;95:e2751.CrossRefPubMedPubMedCentral Liao CT, Chen SJ, Lee LY, et al. An ultra-deep targeted sequencing gene panel improves the prognostic stratification of patients with advanced oral cavity squamous cell carcinoma. Medicine. 2016;95:e2751.CrossRefPubMedPubMedCentral
Metadaten
Titel
Clinical Outcomes of Taiwanese Patients with cT4 Oral Cavity Squamous Cell Carcinoma: Toward the Identification of the Optimal Initial Treatment Approach for cT4b Patients
verfasst von
Chun-Ta Liao, MD
Yu-Wen Wen, PhD
Shu Ru Lee, PhD
Tsang-Wu Liu, MD
Sen-Tien Tsai, MD
Ming-Hsui Tsai, MD
Jin-Ching Lin, MD
Pei-Jen Lou, MD, PhD
Pen-Yuan Chu, MD
Yi-Shing Leu, MD
Kuo-Yang Tsai, MD
Shyuang-Der Terng, MD
Tsung-Ming Chen, MD
Cheng-Hsu Wang, MD
Chih-Yen Chien, MD
Wen-Cheng Chen, MD
Li-Yu Lee, MD
Chien-Yu Lin, MD, PhD
Hung-Ming Wang, MD
Shu-Hang Ng, MD
Chih-Hung Lin, MD
Tuan-Jen Fang, MD
Shiang-Fu Huang, MD, PhD
Chung-Jan Kang, MD
Kai-Ping Chang, MD, PhD
Lan Yan Yang, PhD
Tzu-Chen Yen, MD, PhD
for the Taiwan Oral Cancer Advisory Group
Publikationsdatum
28.11.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5629-x

Weitere Artikel der Ausgabe 3/2017

Annals of Surgical Oncology 3/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.